Even after additional adjustment for PNPLA3 rs738409 and TM6SF2 rs58542926 genotypes, low muscle mass significantly increased the risk of NAFLD (HR, 1.18; 95% CI, 1.11–1.27; Model 3 in Table3). The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.